FDA heavily criticized by independent institute over Biogen approval
Independent US research institute ICER has criticized the FDA over its recent approval, saying it believes more studies are required to alleviate "substantial" uncertainty surrounding Biogen's drug, Aduhelm.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
The US Food and Drug Administration (FDA) approved Biogen's Alzheimer's drug Aduhelm on Monday, and that decision is now being criticized.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen's US Alzheimer's drug may also come to Europe
For subscribers
Biogen passes FDA test for Alzheimer's medicine
For subscribers
Fate of Biogen’s stock rides on Alzheimer’s drug decision
For subscribers
